-
Antonio Garrido Montalban,
Erik Boman,
Chau-Dung Chang,
Susana Conde Ceide,
Russell Dahl,
David Dalesandro,
Nancy G J Delaet,
Eric Erb,
Justin T Ernst,
Andrew Gibbs, [......],
Christopher Lum,
Jan Lundström,
Stephen Miller, Hiroshi Nakanishi,
Edward Roberts,
Eddine Saiah,
Robert Sullivan,
Jan Urban,
Zhijun Wang,
Christopher J Larson
[show abstract]
[hide abstract]
ABSTRACT: We have optimized a novel series of potent p38 MAP kinase inhibitors based on an alpha-ketoamide scaffold through structure based design that due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME, in vivo PK and efficacy studies show these compounds to have drug-like characteristics and have resulted in the nomination of a development candidate which is currently in phase II clinical trials for the oral treatment of inflammatory conditions.
Bioorganic & medicinal chemistry letters 08/2010; 20(16):4819-24. · 2.65 Impact Factor
-
Antonio Garrido Montalban,
Erik Boman,
Chau-Dung Chang,
Susana Conde Ceide,
Russell Dahl,
David Dalesandro,
Nancy G J Delaet,
Eric Erb,
Justin Ernst,
Andrew Gibbs,
Jeffrey Kahl,
Linda Kessler,
Jan Lundström,
Stephen Miller, Hiroshi Nakanishi,
Edward Roberts,
Eddine Saiah,
Robert Sullivan,
Zhijun Wang,
Christopher J Larson
[show abstract]
[hide abstract]
ABSTRACT: The tumor necrosis factor-alpha (TNF-alpha) cytokine, secreted by activated monocytes/macrophages and T lymphocytes, is implicated in several diseases, including rheumatoid arthritis, chronic obstructive pulmonary disease, inflammatory bowel disease, and osteoporosis. Monocyte/macrophage production of TNF-alpha is largely driven by p38alpha mitogen-activated protein kinase (MAP kinase), an intracellular soluble serine-threonine kinase. p38alpha MAP kinase is activated by growth factors, cellular stresses, and cytokines such as TNF-alpha and interleukin-l (IL-I). The primary contribution of p38alpha activation to excess TNF-alpha in settings of both chronic and acute inflammation has instigated efforts to find inhibitors of this enzyme as possible therapies for associated disease states. Analogue design, synthesis, and structure-activity studies led to the identification of 5-tert-butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide (KR-003048) as a potent inhibitor of the p38 MAP kinase signaling pathway in vitro and in vivo. The inhibition in vitro of human p38alpha enzyme activity and lipopolysaccharide (LPS)-induced p38 activation and subsequent TNF-alpha release is described. KR-00348 was demonstrated to be a potent inhibitor of inflammatory cytokine production ex vivo in rat and human whole blood, and showed good oral bioavailability. Additionally, efficacy in mouse and rat models of acute and chronic inflammation was obtained. KR-003048 possessed therapeutic activity in acute models, demonstrating substantial inhibition of carrageenan-induced paw edema and in vivo LPS-induced TNF release at 30mg/kg p.o. Collagen-induced arthritis in mice was significantly inhibited by 10 and 30mg/kg doses of KR-003048. Evidence for disease-modifying activity in this model was indicated by histological evaluation of joints.
European journal of pharmacology 04/2010; 632(1-3):93-102. · 2.59 Impact Factor
-
Antonio Garrido Montalban,
Erik Boman,
Chau-Dung Chang,
Susana Conde Ceide,
Russell Dahl,
David Dalesandro,
Nancy G J Delaet,
Eric Erb,
Andrew Gibbs,
Jeff Kahl,
Linda Kessler,
Jan Lundström,
Stephen Miller, Hiroshi Nakanishi,
Ed Roberts,
Eddine Saiah,
Robert Sullivan,
Zhijun Wang,
Christopher J Larson
[show abstract]
[hide abstract]
ABSTRACT: We have identified a second series of potent p38 inhibitors. As with our first generation series, these compounds are based on an alpha-ketoamide scaffold. The reversal of the ketoamide order, however, introduces more chemical flexibility and in addition results in improve potencies against p38.
Bioorganic & medicinal chemistry letters 10/2008; 18(20):5456-9. · 2.65 Impact Factor
-
Christopher Lum,
Jeff Kahl,
Linda Kessler,
Jeff Kucharski,
Jan Lundström,
Stephen Miller, Hiroshi Nakanishi,
Yazhong Pei,
Kent Pryor,
Edward Roberts,
Lubomir Sebo,
Robert Sullivan,
Jan Urban,
Zhijun Wang
[show abstract]
[hide abstract]
ABSTRACT: The discovery of two classes of pyrimidine-based inhibitors of GSK-3 is described. Optimization of these series led to inhibitors with IC(50)<10nM and >100-fold selectivity over Aurora A kinase. A proposed binding mode of 21b is presented. One compound (33) of the pyrimidine series showed promising pharmacokinetic parameters.
Bioorganic & medicinal chemistry letters 06/2008; 18(12):3578-81. · 2.65 Impact Factor
-
Antonio Garrido Montalban,
Erik Boman,
Chau-Dung Chang,
Susana Conde Ceide,
Russell Dahl,
David Dalesandro,
Nancy G J Delaet,
Eric Erb,
Justin T Ernst,
Andrew Gibbs,
Jeffrey Kahl,
Linda Kessler,
Jan Lundström,
Stephen Miller, Hiroshi Nakanishi,
Edward Roberts,
Eddine Saiah,
Robert Sullivan,
Zhijun Wang,
Christopher J Larson
[show abstract]
[hide abstract]
ABSTRACT: We have identified a novel series of potent p38 MAP kinase inhibitors through structure-based design which due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME and in vivo PK studies show these compounds to have drug-like characteristics which could result in the development of an oral treatment for inflammatory conditions.
Bioorganic & medicinal chemistry letters 04/2008; 18(6):1772-7. · 2.65 Impact Factor
